EPISODE · Nov 9, 2018 · 13 MIN
CEO Dr. Nader Pourhassan of CytoDyn Inc. (OTCQB: CYDY) - Nov '18 update
from Stock Day Media · host Stock Day Media
CEO Dr. Nader Pourhassan of CytoDyn Inc. (OTCQB: CYDY), returns to Stock Day to give a detailed update on status of clinical trials for Pro 140, fast tracking with the FDA for final approval, and hopes to bring to market by 2020. OTCQB: CYDY # PRO 140 # HIV/AIDS therapeutics # biotechnology company # patient safety # Colon Cancer # less frequent dosing # minimal side effects # protects healthy cells # treatment and prevention of HIV # humanized monoclonal antibodies Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy
What this episode covers
CEO Dr. Nader Pourhassan of CytoDyn Inc. (OTCQB: CYDY), returns to Stock Day to give a detailed update on status of clinical trials for Pro 140, fast tracking with the FDA for final approval, and hopes to bring to market by 2020. OTCQB: CYDY # PRO 140 # HIV/AIDS therapeutics # biotechnology company # patient safety # Colon Cancer # less frequent dosing # minimal side effects # protects healthy cells # treatment and prevention of HIV # humanized monoclonal antibodies Advertising Inquiries: https://redcircle.com/brands Privacy & Opt-Out: https://redcircle.com/privacy
NOW PLAYING
CEO Dr. Nader Pourhassan of CytoDyn Inc. (OTCQB: CYDY) - Nov '18 update
No transcript for this episode yet
Similar Episodes
Sep 22, 2023 ·20m
Sep 22, 2023 ·20m
Sep 22, 2023 ·27m
Sep 22, 2023 ·14m
Sep 22, 2023 ·24m
Sep 22, 2023 ·22m